53 results about "Cyclovirus" patented technology

The present invention provides methods for the determination of the viral titer of a culture of host animal host cells infected with a circovirus. The FACS-based methods of the invention may include determining the viability of the host cells in a cell culture medium supernatant and of those cells that remain adherent to a solid support. Detecting and measuring the percentage of cells that expressed the viral antigens ORF1 and ORF2 may determine the viral load of the cultured host cells. The yield of the virus may be established by the detection and measurement of both antigens in supernatant cells, for example 5 to 7 days from when the host cells are transferred to a serum free medium. The methods of the invention may yield rapid quantitative data. This allows the repeated in-process monitoring of the viral production throughout the incubation period, and ready selection of the most appropriate harvesting point.

A composition for treating skin pigmentation, a method of forming the composition, and a method of treating skin pigmentation are disclosed. The composition comprises at least one pharmaceutically acceptable additive. The composition further comprises at least one melanin production inhibitor, which may be a depigmentation agent. The melanin production inhibitor is present in an amount effective to inhibit melanin production in human skin cells of a subject that is administered the composition. The melanin production inhibitor is selected from the group consisting of cyclovirobuxine D, lipoic acid, nuciferine, peimisine, oleuropein, Rhodiola algida extract, Rhodiola kirilowii (Regel) Maxim extract, Glycyrrhizae Radix et Rhizoma extract, Cirsii japonici herba extract, Platycladi semen extract, Synotis erythropappa extract, Astragali complanati semen extract, Plantaginis semen extract, Lycopi herba extract, Euryales semen extract, Cuscutae semen extract, Amomi fructus extract, Tara seed extract, Platycladi cacumen extract, Eucommiae cortex extract, Dioscoreae rhizoma extract, Cirsii herba extract, and combinations thereof.

The invention provides a method for efficiently preparing porcine circovirus 2 type empty capsid, which comprises the following steps: cloning different viral strain lines of antigen genes cap required by forming circovirus empty capsid and artificially reconstructed cap mutant into a domestic silkworm baculovirus carrying vector to obtain a homologous recombinant vector, recombining or transpositioning the homologous recombinant vector and parent virus DNA (deoxyribonucleic acid) in an insect cell or bacterium to obtain recombinant baculovirus, and infecting the insect with the recombinant baculovirus containing the antigen gene; and culturing the infected insect host to express the corresponding circovirus 2 type empty capsid, determining the information required by efficiently assembling the virus empty capsid by comparison and experimentation, and obtaining a recombinant viral strain line capable of efficiently expressing and assembling virus empty capsid, thereby carrying out mass production on the circovirus 2 type empty capsid. The porcine circovirus 2 type empty capsid produced by the method can be used for preparing vaccines for preventing and treating porcine circovirus disease after being subjected to primary purification.

The invention provides a cell line highly sensitive to a porcine circovirus type 2 (PCV2) and discloses a preparation method of the cell line. After the PCV2 is adopted to infect PK-15 cells, expression of 3-hydroxyl-3-HMG-CoAreductase (HMGCR) is obviously changed; and after HMGCR genes are subjected to silence, TCID50 (tissue culture infectious dose 50) of the PCV2 reaches 108.5 / ml. An HMGCR gene silence cell line can be obtained by RNA (ribonucleic acid) interfering technology, and the cell line highly sensitive to the PCV2 can be finally obtained through screening. By utilizing HMGCR gene silence cells prepared by the method to culture the PCV2, high-titer viruses can be obtained, and studying on pathogenesis of the PCV2, virus culturing and development and industrial production of totivirus inactivated vaccines are facilitated.

A porcine circovirus type 3 virus strain and a vaccine composition prepared from the immunogenic substance of the strain are described. The porcine circovirus type 3 virus strain has good immunogenicity, and the prepared vaccine composition can provide complete protection against varies of porcine circovirus type 3 viruses from different sources.